B67

JP 4244015	A	19920901	JP 9132877	A	19910227	199241	B
JP 3204675	B2	20010904	JP 9132877	A	19910227	200152	

Priority Applications (No Type Date): JP 90405007 A 19901221
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
JP 4244015	A		6	A61K-009/00	
JP 3204675	B2		6	A61L-027/00	Previous Publ. patent JP 4244015

Abstract (Basic): JP 4244015 A

Prepn. comprises inclusion and fixation of pancreatic Langerhans islet with natural and/or synthetic polymer and subsequent cultivation in-vitro for 5 days or more.

Fixing materials from natural polymers employable are agarose, agarose acid hydrolysate, koppa-carrageenan, collagen, gelatin, gellan gum, gum arabic, alginic acid salts, pectin, agar, mannan, fibrin, chitosan, etc.. The materials from synthetic polymers are photo-bridged PVA, isopropyl-acrylamide copolymer polyacrylamide, etc.. Mixed materials are e.g. polyionic complexes such as alginic acid-polylysine and CMC-polylysine. Pref. inclusion is carried out by gelation.

USE/ADVANTAGE - The prepn. solves problems caused by damaged pancreatic Langerhans islet. It can also avoid hypoglycemia of animals which have undergone organ transplant and further prevent the immunoinduction of recipients.

In an example, agarose (0.15g) were added to 3ml Eagle's MEM soln. to make 5 wt. % polymer concn.. This was autoclaved at 121 deg. C for 20 mins. and than the resultant soln. was kept at 40 deg. C. A dispersion liq. of 1000 pancreatic Langerhans islets (isolated from hamster's pancreas by collagenase method) in 0.1 ml Eagles's MEM soln. was added to the soln.. To this was added ca. 20 ml liq. paraffin at 40 deg. C to give a dispersion liq. which was ice cooled into a gel. After addn. of ca. 30 ml Hanks' soln., the mixt. was centrifuged at 2000 rpm for 10 mins. to collect pptd. microcapsules of ca. 50-80 um particle size. Each capsule contained 1-several islets included and fixed. These microcapsules were cultivated in eagle's MEM-5% fetal bovine serum under 5% CO2 at 37 deg. C for 30 days to form hydrid-type artificial pancrea

Dwg.0/0

```
? S PN=JP 7216000
      S5         1  PN=JP 7216000
? T 5/3,AB/1
```

5/3,AB/1

DIALOG(R)File 351:Derwent WPI

010416170
WPI Acc No: 1995-317484/*199541*
XRAM Acc No: C95-140942

Combined prod. of a monoclonal antibody against epithelium growth factor receptor and spacer - selectively recognises only cells producing EGF receptor

Patent Assignee: KIYOMIZU N (KIYO-I); SHIBAYAGI KK (SHIB-N)
Number of Countries: 001 Number of Patents: 001
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
JP 7216000	A	19950815	JP 9440326	A	19940131	199541	B

[redacted]

Priority Applications (No Type Date): JP 9440326 A 19940131
Patent Details:
Patent No Kind Lan Pg Main IPC Filing Notes
JP 7216000 A 8 C07K-016/28

Abstract (Basic): JP 7216000 A

Combined prod. of a monoclonal antibody against epithelium growth factor (EGF) receptor, consists of the monoclonal antibody against EGF receptor and a spacer.

Also claimed are (A) a complex of a monoclonal antibody against EGF receptor in which monoclonal antibody against EGF receptor is combined to gene via spacer or directly, (B) method for introduction of the complex into a cell through an EGF receptor, (C) prepn. of a combined prod. of a monoclonal antibody against EGF receptor in which the monoclonal antibody against EGF receptor is combined to a spacer, and (D) prepn. of a complex of a monoclonal antibody against EGF receptor in which the monoclonal antibody against EGF receptor is combined to a gene through a spacer or directly.

ADVANTAGE - Combined prod. and complex can recognise only cells producing EGF receptor as target. Method can introduce any gene to a cell.

In an example, IgG2 mouse monoclonal antibody immunologically reacting with low affinity EGF receptor was prepd. by a hybridoma cell line. Thus, BALB/c mouse spleen cell immunised by human cancroid cell was fused with mouse myeloma cell. Hybridoma sub-clone was cultured and IgG obtd. from cell was purified by ammonium sulphate pptn. and a DEAE Cellulose column. Resultant monoclonal antibody was confirmed to be IgG. It was modified by dithiopyridyl gps. Polylysine was modified by 2-iminothiorane. Modified monoclonal antibody was combined to the modified polylysine. The combined prod/DNA complex was prepd.

Dwg.0/4

? S PN=JP 57163318
S6 1 PN=JP 57163318
? T 6/3,AB/1

6/3,AB/1

DIALOG(R)File 351:Derwent WPI

003550275
WPI Acc No: 1982-98272E/*198246*
Human beta-interferon antigen prepn. - by reacting N-terminal peptide of interferon with carrier in presence of hapten-carrier binder
Patent Assignee: OTSUKA PHARM CO LTD (SAKA)
Number of Countries: 001 Number of Patents: 001
Patent Family:
Patent No Kind Date Applicat No Kind Date Week
JP 57163318 A 19821007 198246 B

Priority Applications (No Type Date): JP 8147841 A 19810331
Patent Details:
Patent No Kind Lan Pg Main IPC Filing Notes
JP 57163318 A 23

Abstract (Basic): JP 57163318 A

Prodn. of human beta-interferon antigen (I) comprises reacting an